using tirzepatide and retatrutide together vs Tirzepatide: GLP-1, GIP & Glucagon How To Switch From Tirzepatide

In SURPASS-2, severe hypoglycemia (requiring third-party assistance) occurred in fewer than 0.6% of tirzepatide-treated participants not on sulfonylureas or insulin, mechanistically expected given the glucose-dependent clamp

When treatment stops prematurely, patients often regain 5070% of lost weight within one year because the underlying metabolic and hormonal drivers of excess hunger remain unaddressed

Semaglutide is a GLP-1 receptor agonist that mimics a natural hormone in the body to help regulate blood sugar and appetite

In the SURMOUNT-1 trial published in the New England Journal of Medicine, adults without diabetes receiving the highest dose of tirzepatide (15 mg weekly) achieved an average weight loss of 20.9% of their initial body weight over 72 weeks, compared to 3.1% with placebo